Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review
This list of RRMM prognostic factors can be used in comparative analyses to assess treatment effectiveness in the absence of head-to-head trials.
Authors
- Beatrice Suero
- Abril Oliva Ramirez
- Leena Patel (ORCID: https://orcid.org/0000-0003-3998-736X)
- Katja Christina Weisel (ORCID: https://orcid.org/0000-0001-9422-6614)
- Shaji Kunnathu Kumar (ORCID: https://orcid.org/0000-0001-5392-9284)
- Sundar Jagannath (ORCID: https://orcid.org/0000-0003-2934-6518)
- Paul Spin (ORCID: https://orcid.org/0000-0002-4622-3547)
- Christian Hampp (ORCID: https://orcid.org/0000-0002-1094-6364)
- Xavier P Leleu (ORCID: https://orcid.org/0000-0002-9822-4170)
- Samantha Craigie
- Wenzhen Ge (ORCID: https://orcid.org/0000-0001-6106-4030)
- Rakesh Popat (ORCID: https://orcid.org/0000-0001-6553-4618)
- Qiufei Ma
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- Universität Hamburg (DE)
- Regeneron (United States) (US)
- Université de Poitiers (FR)
- Mount Sinai Hospital (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- EVERSANA (Canada) (CA)
- University College London (GB)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.clml.2025.03.013
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54
Funders
- Regeneron Pharmaceuticals